• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

衡量药品监管机构的多维声誉:一种面向公众的量表的开发与验证

Measuring the multidimensional reputation of a medicines regulatory agency: development and validation of a public-oriented scale.

作者信息

Son Kyung-Bok

机构信息

College of Pharmacy, Hanyang University, Ansan, Republic of Korea.

出版信息

Front Med (Lausanne). 2025 Apr 30;12:1570817. doi: 10.3389/fmed.2025.1570817. eCollection 2025.

DOI:10.3389/fmed.2025.1570817
PMID:40370744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12075541/
Abstract

OBJECTIVE

The reputation of public agencies, encompassing the dimensions of performance, morality, procedure, and technical competence, is fundamental to understanding their behavior. However, standardized, individual-level measures of reputation suitable for surveys targeting the general public are lacking. This study aims to develop and validate a survey instrument for the general public to measure the multi-dimensional reputation of public agencies, with a focus on South Korea's medicines regulatory agency.

METHODS

Survey items were developed based on previous literature, refined through expert consultation, and validated through a population survey. The validation study involved 1,000 participants from the public, selected using a quota sampling method stratified by age, sex, and region, according to the South Korean census. Validity was assessed through exploratory factor analysis and hypothesis testing, while reliability was evaluated using internal consistency.

RESULTS

Exploratory factor analysis identified a three-dimensional structure of reputation, encompassing performance, procedure, and technical competence, while morality was not distinctly identified as a separate dimension. Construct validity, including convergent and discriminant validity, was confirmed. The internal consistency of the three dimensions was acceptable, with Cronbach's alpha coefficients ranging from 0.87 to 0.91. The overall reputation of the medicines regulatory agency was measured at 72 out of 100. The specific dimension scores were as follows: 74 for technical competence, 71 for performance, and 70 for procedure.

CONCLUSION

The agency should recognize the multidimensional nature of reputation and foster an environment that enables the public to observe and evaluate these dimensions. Reputation management strategies should emphasize not only technical expertise but also performance and procedural aspects to ensure a well-rounded reputation.

摘要

目的

公共机构的声誉,包括绩效、道德、程序和技术能力等方面,对于理解其行为至关重要。然而,目前缺乏适用于针对普通公众的调查的标准化、个体层面的声誉衡量指标。本研究旨在开发并验证一种面向普通公众的调查工具,以衡量公共机构的多维度声誉,重点关注韩国药品监管机构。

方法

调查项目基于以往文献制定,经专家咨询完善,并通过人口调查进行验证。验证研究涉及1000名公众参与者,采用配额抽样方法,根据韩国人口普查按年龄、性别和地区分层选取。通过探索性因素分析和假设检验评估效度,使用内部一致性评估信度。

结果

探索性因素分析确定了声誉的三维结构,包括绩效、程序和技术能力,而道德并未被明确识别为一个单独维度。包括收敛效度和区分效度在内的结构效度得到确认。三个维度的内部一致性可接受,克朗巴哈系数在0.87至0.91之间。药品监管机构的总体声誉在100分中得分为72分。具体维度得分如下:技术能力74分,绩效71分,程序70分。

结论

该机构应认识到声誉的多维度性质,并营造一个使公众能够观察和评估这些维度的环境。声誉管理策略不仅应强调技术专长,还应注重绩效和程序方面,以确保全面的声誉。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/143f/12075541/1ca7a7eb2b29/fmed-12-1570817-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/143f/12075541/1ca7a7eb2b29/fmed-12-1570817-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/143f/12075541/1ca7a7eb2b29/fmed-12-1570817-g001.jpg

相似文献

1
Measuring the multidimensional reputation of a medicines regulatory agency: development and validation of a public-oriented scale.衡量药品监管机构的多维声誉:一种面向公众的量表的开发与验证
Front Med (Lausanne). 2025 Apr 30;12:1570817. doi: 10.3389/fmed.2025.1570817. eCollection 2025.
2
A Multidimensional Reputation Barometer for Public Agencies: A Validated Instrument.公共机构的多维声誉晴雨表:一种经过验证的工具。
Public Adm Rev. 2020 May-Jun;80(3):415-425. doi: 10.1111/puar.13158. Epub 2020 Feb 18.
3
[Development and validation of a questionnaire to measure hospitals' social reputation].[用于衡量医院社会声誉的问卷的开发与验证]
Gac Sanit. 2012 Sep-Oct;26(5):444-9. doi: 10.1016/j.gaceta.2011.11.020. Epub 2012 Apr 3.
4
Development and validation of the multi-dimensional health resilience scale for community-dwelling adults.社区居住成年人多维健康恢复力量表的编制与验证
Front Public Health. 2025 Feb 12;13:1452738. doi: 10.3389/fpubh.2025.1452738. eCollection 2025.
5
Development and validation of the Health Activation Scale for Children (HAS-C): an important intermediate outcome measure for health promotion initiatives.发展和验证儿童健康激活量表(HAS-C):健康促进干预措施的重要中间结果测量指标。
BMC Health Serv Res. 2024 Sep 27;24(1):1120. doi: 10.1186/s12913-024-11526-7.
6
Validation of the Korean Version of the Assessment of Strategies in Families-Effectiveness Scale.《家庭策略有效性评估量表(韩文版)》的验证。
J Nurs Res. 2023 Oct 1;31(5):e290. doi: 10.1097/jnr.0000000000000569.
7
Validation of the Korean Version of the Community Assessment of Psychic Experiences in General Population.一般人群心理体验社区评估韩国版的验证
Psychiatry Investig. 2023 Jul;20(7):625-634. doi: 10.30773/pi.2023.0011. Epub 2023 Jul 12.
8
Development and validation of safety climate scales for mobile remote workers using utility/electrical workers as exemplar.开发并验证使用电力/电工作为范例的移动远程工作者安全氛围量表。
Accid Anal Prev. 2013 Oct;59:76-86. doi: 10.1016/j.aap.2013.04.030. Epub 2013 May 10.
9
Development and validation of self-management scale for tuberculosis patients.结核病患者自我管理量表的编制与验证。
BMC Infect Dis. 2022 May 27;22(1):502. doi: 10.1186/s12879-022-07483-3.
10
[French validation of the Verona Service Satisfaction Scale-VSSS-54F].[《维罗纳服务满意度量表 - VSSS - 54F》的法语验证]
Encephale. 2003 Mar-Apr;29(2):110-8.

本文引用的文献

1
Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022.支持美国食品药品监督管理局2015年至2022年加速批准的临床证据强度。
BMC Med. 2024 Dec 18;22(1):587. doi: 10.1186/s12916-024-03800-6.
2
Drug Review and Approval Policies Based on Real-world Evidence in China and the United States: A Comparative Study.基于真实世界证据的中美药品审评审批政策:一项比较研究。
Clin Ther. 2024 Dec;46(12):1059-1068. doi: 10.1016/j.clinthera.2024.09.009. Epub 2024 Oct 5.
3
Benchmarking Drug Regulatory Systems for Capacity Building: An Integrative Review of Tools, Practice, and Recommendations.
药物监管系统能力建设的基准测试:工具、实践和建议的综合回顾。
Int J Health Policy Manag. 2023;12:8100. doi: 10.34172/ijhpm.2023.8100. Epub 2023 Oct 16.
4
Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making.利用社交媒体作为药物研发和监管决策的真实世界数据来源。
Drug Saf. 2024 May;47(5):495-511. doi: 10.1007/s40264-024-01409-5. Epub 2024 Mar 6.
5
Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.真实世界证据在欧洲药品管理局监管决策中的贡献。
Clin Pharmacol Ther. 2023 Jan;113(1):135-151. doi: 10.1002/cpt.2766. Epub 2022 Nov 4.
6
Perceptions of Regulatory Decision-Making for New Drugs From the Viewpoints of the Manufacturers in South Korea.从韩国制造商视角看新药监管决策
Front Med (Lausanne). 2022 Mar 30;9:869262. doi: 10.3389/fmed.2022.869262. eCollection 2022.
7
Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.用于监管决策的真实世界证据:来自世界各地的指南。
Clin Ther. 2022 Mar;44(3):420-437. doi: 10.1016/j.clinthera.2022.01.012. Epub 2022 Feb 15.
8
Using cognitive interviews and think-aloud protocols to understand thought processes.使用认知访谈和出声思维法来理解思维过程。
Curr Pharm Teach Learn. 2021 Feb;13(2):181-188. doi: 10.1016/j.cptl.2020.09.005. Epub 2020 Oct 14.
9
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.FDA 和 EMA 加速审批计划与新药的治疗价值之间的关联:回顾性队列研究。
BMJ. 2020 Oct 7;371:m3434. doi: 10.1136/bmj.m3434.
10
The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity.世卫组织全球基准工具:加强国家监管能力的游戏规则改变者。
BMJ Glob Health. 2020 Aug;5(8). doi: 10.1136/bmjgh-2020-003181.